FDA approves Ipsen's Somatuline Depot for carcinoid syndrome

Ipsen Group (Euronext:IPN; Pink:IPSEY) said FDA approved Somatuline Depot lanreotide acetate (ITM-014) to treat carcinoid syndrome.

The extended-release formulation of somatostatin analog lanreotide is already approved in the U.S. to treat acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The product is approved to treat acromegaly and neuroendocrine tumors in 70 countries, and is marketed outside the U.S. as Somatuline Autogel...